Objective: To assess the association between over-the-counter analgesic (OTCA) use and hospitalization for liver-associated events in cirrhotic patients.
Material And Methods: Ninety adult cirrhotics admitted with liver-associated events and 126 non-hospitalized cirrhotic controls were enrolled prospectively into a case-control study. Standardized questionnaires were used to obtain predictor variables, including detailed 30-day OTCA use. Data were analyzed via logistic regression.
Results: Hepatitis C (43%), alcohol (34%), and cryptogenic (13%) were the most common etiologies of cirrhosis. OTCA use was similar between cases and controls in the 30 days prior to enrollment (34% vs. 44%; odds ratio, OR = 0.66, 95% confidence interval, CI = 0.37-1.16, p = 0.148). Adjusted analyses also found no significant association between OTCA use and hospitalization for liver-associated events (OR = 0.73, 95% CI = 0.38-1.38, p = 0.330). Furosemide (p = 0.001), lactulose (p = 0.026), and number of prior liver-associated events (p = 0.002) were positively associated with hospitalization, while propranolol showed an inverse association (p = 0.008).
Conclusion: Our data suggest that non-excessive OTCA use is not significantly associated with hospitalization for liver-associated events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365521003663704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-dose tolvaptan to control disease progression in Chinese patients with autosomal dominant polycystic kidney disease: a retrospective cohort study.
Transl Androl Urol
October 2024
Department of Nephrology, China-Japan Friendship Hospital, Beijing, China.
Article Synopsis
- The study investigated the effectiveness of a lower dose of tolvaptan for treating autosomal dominant polycystic kidney disease (ADPKD) among Chinese patients, as there was limited information on optimal dosing for this population.
- Conducted as a retrospective cohort study, 43 patients were treated with tolvaptan for at least 12 months, starting with a morning/evening dose of 7.5 mg, and adjustments were made based on individual responses.
- Results showed a significant improvement in kidney function (eGFR) and reduced kidney volume growth after 12 months of treatment, with manageable side effects primarily consisting of mild thirst reported by about half of the participants.
Burden of Portal Hypertension Complications Is Greater in Liver Transplant Wait-Listed Registrants with End-Stage Liver Disease and Type 2 Diabetes.
Dig Dis Sci
September 2024
Division of Gastroenterology and Hepatology, Virginia Commonwealth University School of Medicine, Richmond, USA.
Article Synopsis
- The study investigates how type 2 diabetes mellitus (T2DM) affects patients with end-stage liver disease who are on a liver transplantation waiting list.
- It includes 593 adult patients registered for liver transplant between 2010 and 2017 and assesses various clinical outcomes over a year, such as hospitalizations and the likelihood of receiving a transplant.
- Results indicate that patients with T2DM experience worse clinical outcomes, such as a higher risk of complications and lower chances of receiving a liver transplant, suggesting that the MELD score may not adequately reflect these risks.
Lifetime Risk of Hepatorenal Events Assessed in Longitudinal Cohort of Renal Transplant Recipients with HBV Infection.
Transplant Proc
September 2023
Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan; School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan; Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan.
Background: Kidney transplantation is a treatment option for patients with end-stage renal disease (ESRD) who are infected with hepatitis B virus (HBV). However, the impact of nucleos(t)ide analogues usage on the clinical outcomes in HBV-infected ESRD patients undergoing kidney transplantation is not well understood. This study aimed to assess the outcomes of kidney transplant recipients with HBV infection using real-world data to provide insight into the disease course over time.
View Article and Find Full Text PDFValidation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Clin Gastroenterol Hepatol
October 2023
Target RWE, Durham, NC.
Background & Aims: There is an unmet need to validate simple and easily available methods that can be used in routine practice to identify those at risk of adverse outcomes from nonalcoholic fatty liver disease (NAFLD). A retrospective-prospective analysis of NAFLD patients enrolled in a longitudinal noninterventional study (TARGET-NASH) was performed to validate the prognostic utility of the following risk-categories: (A) Fibrosis-4 (FIB-4) <1.3 and/or liver-stiffness measurement (LSM) measured by Fibroscan <8 kp, (B) FIB-4 1.
View Article and Find Full Text PDFPathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients.
Biomolecules
January 2023
Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
The global outbreak of COVID-19 possesses serious challenges and adverse impacts for patients with progression of chronic liver disease and has become a major threat to public health. COVID-19 patients have a high risk of lung injury and multiorgan dysfunction that remains a major challenge to hepatology. COVID-19 patients and those with liver injury exhibit clinical manifestations, including elevation in ALT, AST, GGT, bilirubin, TNF-α, and IL-6 and reduction in the levels of CD4 and CD8.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!